 The FDA has signed off Lipocine Incs NASDAQ: LPCN Investigational New Drug Application IND to initiate a Phase 2 study to evaluate LPCN 1154 for the treatment of postpartum depression PPD in adults. A pharmacokinetic PK study to assess dose proportionality is planned to start in July 2021, with top-line results expected in the third quarter of 2021. 